We are proud to announce the grant of our European patent EP 4 090 334 B1 which protects the combination of diltiazem and baloxavir marboxil for use in the prevention and/or treatment of influenza virus infections, and representing a significant milestone in our commitment to innovative antiviral strategies.

In a context where influenza infections continue to pose serious public health threats —due to the emergence of variants reducing vaccine efficacy and compromising current antiviral treatments— host-directed therapies offer promising broad-spectrum alternatives.

Our research has identified diltiazem as a first-in-class modulator of the endogenous IFNλ response, capable of inducing a broad-spectrum antiviral state in human respiratory epithelia. Using software-assisted combinatorial analyses, we demonstrated in both respiratory cell lines and reconstructed Human Airway Epithelia HAE that the combination with baloxavir marboxil significantly enhances antiviral efficacy and helps delay or prevent the emergence of antiviral resistance.

These findings reinforce the relevance of our host-directed combination approach to complement and potentiate current direct-acting antivirals and provide new strategies to address antiviral resistance and future pandemic threats. With the granting of this new patent, we continue to expand our portfolio of host-targeted therapies (EP 3 270 968 B1 ; CAN 2 979 784 B2 ; US 12 285 433 B2) designed to respond to seasonal and pandemic respiratory viral threats.

For more information, see patent and publication:
https://lnkd.in/etsMB3-N
https://lnkd.in/edMvs3Z6